175 related articles for article (PubMed ID: 22385476)
1. Structure-activity relationships in human Toll-like receptor 2-specific monoacyl lipopeptides.
Salunke DB; Shukla NM; Yoo E; Crall BM; Balakrishna R; Malladi SS; David SA
J Med Chem; 2012 Apr; 55(7):3353-63. PubMed ID: 22385476
[TBL] [Abstract][Full Text] [Related]
2. Structure-activity relationships in toll-like receptor 2-agonists leading to simplified monoacyl lipopeptides.
Agnihotri G; Crall BM; Lewis TC; Day TP; Balakrishna R; Warshakoon HJ; Malladi SS; David SA
J Med Chem; 2011 Dec; 54(23):8148-60. PubMed ID: 22007676
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and Evaluation of Novel TLR2 Agonists as Potential Adjuvants for Cancer Vaccines.
Lu BL; Williams GM; Verdon DJ; Dunbar PR; Brimble MA
J Med Chem; 2020 Mar; 63(5):2282-2291. PubMed ID: 31418565
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationships in toll-like receptor-2 agonistic diacylthioglycerol lipopeptides.
Wu W; Li R; Malladi SS; Warshakoon HJ; Kimbrell MR; Amolins MW; Ukani R; Datta A; David SA
J Med Chem; 2010 Apr; 53(8):3198-213. PubMed ID: 20302301
[TBL] [Abstract][Full Text] [Related]
5. Immunostimulants and Toll-like receptor ligands obtained by screening combinatorial lipopeptide collections.
Reutter F; Jung G; Baier W; Treyer B; Bessler WG; Wiesmüller KH
J Pept Res; 2005 Mar; 65(3):375-83. PubMed ID: 15787968
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, evaluation and molecular dynamics study of human toll-like receptor 2/6 specific monoacyl lipopeptides as candidate immunostimulants.
Zhu Y; Liu B; Chen Z; Wang X; Wang Y; Zhang W; Wang S; Zhang M; Li Y
Bioorg Chem; 2023 Dec; 141():106823. PubMed ID: 37708825
[TBL] [Abstract][Full Text] [Related]
7. N-tetradecylcarbamyl lipopeptides as novel agonists for Toll-like receptor 2.
Willems MM; Zom GG; Khan S; Meeuwenoord N; Melief CJ; van der Stelt M; Overkleeft HS; Codée JD; van der Marel GA; Ossendorp F; Filippov DV
J Med Chem; 2014 Aug; 57(15):6873-8. PubMed ID: 25019313
[TBL] [Abstract][Full Text] [Related]
8. Design and development of stable, water-soluble, human Toll-like receptor 2 specific monoacyl lipopeptides as candidate vaccine adjuvants.
Salunke DB; Connelly SW; Shukla NM; Hermanson AR; Fox LM; David SA
J Med Chem; 2013 Jul; 56(14):5885-900. PubMed ID: 23795818
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of thiol-reactive lipopeptide adjuvants. Incorporation into liposomes and study of their mitogenic effect on mouse splenocytes.
Roth A; Espuelas S; Thumann C; Frisch B; Schuber F
Bioconjug Chem; 2004; 15(3):541-53. PubMed ID: 15149182
[TBL] [Abstract][Full Text] [Related]
10. Toll-like receptor 6-independent signaling by diacylated lipopeptides.
Buwitt-Beckmann U; Heine H; Wiesmüller KH; Jung G; Brock R; Akira S; Ulmer AJ
Eur J Immunol; 2005 Jan; 35(1):282-9. PubMed ID: 15580661
[TBL] [Abstract][Full Text] [Related]
11. Structural requirement for the agonist activity of the TLR2 ligand Pam2Cys.
Zeng W; Eriksson E; Chua B; Grollo L; Jackson DC
Amino Acids; 2010 Jul; 39(2):471-80. PubMed ID: 20091415
[TBL] [Abstract][Full Text] [Related]
12. Simple synthetic toll-like receptor 2 ligands.
Abdel-Aal AB; Al-Isae K; Zaman M; Toth I
Bioorg Med Chem Lett; 2011 Oct; 21(19):5863-5. PubMed ID: 21855334
[TBL] [Abstract][Full Text] [Related]
13. Lipopeptide structure determines TLR2 dependent cell activation level.
Buwitt-Beckmann U; Heine H; Wiesmüller KH; Jung G; Brock R; Ulmer AJ
FEBS J; 2005 Dec; 272(24):6354-64. PubMed ID: 16336272
[TBL] [Abstract][Full Text] [Related]
14. TLR2 agonists and their structure-activity relationships.
Lu BL; Williams GM; Brimble MA
Org Biomol Chem; 2020 Jul; 18(27):5073-5094. PubMed ID: 32582902
[TBL] [Abstract][Full Text] [Related]
15. Lipolanthionine peptides act as inhibitors of TLR2-mediated IL-8 secretion. Synthesis and structure-activity relationships.
Seyberth T; Voss S; Brock R; Wiesmüller KH; Jung G
J Med Chem; 2006 Mar; 49(5):1754-65. PubMed ID: 16509590
[TBL] [Abstract][Full Text] [Related]
16. Development of
Zhou Y; Banday AH; Hruby VJ; Cai M
Molecules; 2019 Sep; 24(19):. PubMed ID: 31569697
[TBL] [Abstract][Full Text] [Related]
17. Prevention and mitigation of acute radiation syndrome in mice by synthetic lipopeptide agonists of Toll-like receptor 2 (TLR2).
Shakhov AN; Singh VK; Bone F; Cheney A; Kononov Y; Krasnov P; Bratanova-Toshkova TK; Shakhova VV; Young J; Weil MM; Panoskaltsis-Mortari A; Orschell CM; Baker PS; Gudkov A; Feinstein E
PLoS One; 2012; 7(3):e33044. PubMed ID: 22479357
[TBL] [Abstract][Full Text] [Related]
18. Synthetic lipopeptide adjuvants and Toll-like receptor 2--structure-activity relationships.
Spohn R; Buwitt-Beckmann U; Brock R; Jung G; Ulmer AJ; Wiesmüller KH
Vaccine; 2004 Jun; 22(19):2494-9. PubMed ID: 15193414
[TBL] [Abstract][Full Text] [Related]
19. Identification and immunological evaluation of novel TLR2 agonists through structure optimization of Pam
Du X; Qian J; Wang Y; Zhang M; Chu Y; Li Y
Bioorg Med Chem; 2019 Jul; 27(13):2784-2800. PubMed ID: 31101493
[TBL] [Abstract][Full Text] [Related]
20. Geometry of a TLR2-Agonist-Based Adjuvant Can Affect the Resulting Antigen-Specific Immune Response.
Wijayadikusumah AR; Zeng W; McQuilten HA; Wong CY; Jackson DC; Chua BY
Mol Pharm; 2019 May; 16(5):2037-2047. PubMed ID: 30924661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
